Your session is about to expire
← Back to Search
Combination Therapy with Cediranib, Olaparib, and Durvalumab for Advanced Solid Tumors(DAPPER Trial)
DAPPER Trial Summary
This trial is studying a combination of two drugs, olaparib and durvalumab or cediranib and durvalumab, in people with advanced cancer of the colon or rectum, pancreas, or uterus.
- Pancreatic Adenocarcinoma
- Colorectal Cancer
DAPPER Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
DAPPER Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2022 Phase 2 trial • 46 Patients • NCT03003520
Awards & Highlights
DAPPER Trial Design
Find a Location
Who is running the clinical trial?
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Share this study with friends